Oncology nursing students across eight states experienced numerous collaborative and learning opportunities while taking part in a novel virtual classroom academic program, according to a presentation by participants.
Carrie Daly, MS, RN, APN, AOCN, is a nurse who has a very rich life because of her job. She has worked tirelessly over a number of years to help hundreds of cancer patients and survivors.
Adding rituximab to fludarabine and cyclophosphamide chemotherapy improves overall survival (OS) in patients with advanced, symptomatic chronic lymphocytic leukemia (CLL) compared with chemotherapy alone, according to a study by German researchers.
The addition of bortezomib to a standard regimen for patients newly diagnosed with multiple myeloma resulted in sustained im provements in quality of life, compared with the standard two-drug regimen, according to long-term re sults from the landmark Velcade as Initial Standard Therapy in Multiple Myeloma (VISTA) trial, which led to the approval of bortezomib for this indication.
Patients receiving the neurokinin 1 (NK1) antagonist aprepitant as part of a preparative regimen prior to stem-cell transplant had improved control of acute and delayed nausea and vomiting, and the drug did not interfere with antitumor efficacy, according to investigators from a prospective, randomized, double-blind, phase 3 trial.
Debate continues as to whether all patients with early human epidermal growth factor receptor type 2 (HER2)+ breast cancer need an anthracycline with trastuzumab. Updated data from the Breast Cancer International Research Group (BCIRG)-006 trial suggest that eliminating the anthracycline will have comparable efficacy and be less toxic.
To sign up for our newsletter or print publications, please enter your contact information below.
